More than 16,000 doses of Ervebo vaccine arrive in Ebola-hit DR Congo

The doses are the first of 70,000 allocated for Kinshasa as experts warn of the virus’s exponential spread.The Democratic Republic of the Congo (DRC) has received more than 16,000 doses of the Ervebo vaccine as the country faces its deadliest-ever Ebola outbreak.The 16,250 doses arrived in the capital, Kinshasa, late on Friday evening, comprising the first of 70,000 that the World Health Organization (WHO) and partners pledged to provide on Thursday.Recommended Stories list of 4 itemslist 1 of 4Ebola outbreak ‘growing faster, ⁠⁠wider’ as DRC death toll passes 2,500: UNlist 2 of 4DR Congo to receive 70,000 doses of Ervebo vaccine as Ebola infections surgelist 3 of 4How Ebola became the deadliest outbreak in DR Congo’s historylist 4 of 4DR Congo’s Ebola outbreak ‘global emergency’ as infections pass 5,000: WHOend of listMore doses are set to arrive next week.Although the vaccine is approved against the Zaire strain of the virus, the Bundibugyo strain currently circulating in the country has no approved vaccine or treatment.Early data from animal trials show it may offer some protection, according to the WHO.Samuel Roger Kamba, the DRC’s health minister, told reporters Ervebo had been used several times in the past, including “on a very large scale” during the 2018 to 2020 outbreak.Of the 70,000 doses intended for the DRC, 20,000 will be part of a late-stage clinical trial to test its effect on the Bundibugyo strain, the WHO said. The remainder is allocated to front-line and health workers.The outbreak has killed more than 2,500 people out of nearly 5,300 confirmed cases, with the United Nations warning this week that infections continue to spread “exponentially”.Although the outbreak was declared in mid-May, it is believed to have started weeks beforehand. Data from the Africa Centres for Disease Control and Prevention, meanwhile, shows that transmission has not yet peaked and could reach three times its known rate.Efforts to contain the virus have been stymied by ongoing armed conflict, delays in identifying cases and a lack of infrastructure in eastern DRC, experts say.